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By analyzing the exomes of 12,332 unrelated Swedish individuals – including 4,877 affected with 
schizophrenia – in ways informed by exome sequences from 45,376 other individuals, we 
identified 244,246 coding-sequence and splice-site ultra-rare variants (URVs) that were unique to 
individual Swedes. We found that gene-disruptive and putatively protein-damaging URVs (but not 
synonymous URVs) were more abundant in schizophrenia cases than controls (P = 1.3 × 10−10). 
This elevation of protein-compromising URVs was several times larger than an analogously 
elevated rate for de novo mutations, suggesting that most rare-variant effects on schizophrenia risk 
are inherited. Among individuals with schizophrenia, the elevated frequency of protein-
compromising URVs was concentrated in brain-expressed genes, particularly in neuronally 
expressed genes; most of this genetic signal arose from large sets of genes whose RNAs have been 
found to interact with synaptically localized proteins. Our results suggest that synaptic dysfunction 
may mediate a large fraction of strong, individually rare genetic influences on schizophrenia risk.
Schizophrenia is a psychiatric disorder with a lifetime risk of about 0.7%1 and a heritability 
of 60–80%2,3 despite greatly reduced reproductive fecundity4,5. Because individuals affected 
with schizophrenia have fewer offspring, purifying selection is expected to prevent high-risk 
alleles from reaching even modest allele frequencies6. Indeed, estimates of selection (when 
based only on the reproductive costs of schizophrenia) may underestimate the actual 
selective pressure against such alleles given emerging evidence that such alleles have 
multiple adverse effects: for example, rare copy number variations (CNVs), implicated with 
penetrances ranging from 2–30% (the latter observed for 22q11.2 deletions), negatively 
impact cognition and fecundity even in their more-typical presentation without 
schizophrenia7. To the extent that such observations condition expectations for rare single-
nucleotide variants, variants with a large effect on schizophrenia risk are likely to be rare in 
populations, requiring sequencing to find them.
Distinguishing those variants that are extremely rare from variants that are segregating in a 
population is ideally informed by sequencing very-large numbers of individuals from the 
same population. We thus analyzed the sequences of 12,332 unrelated individuals (4,946 
affected with schizophrenia, 6,242 unaffected controls, and 1,144 with other psychiatric 
illnesses whose analysis is beyond the scope of the current study) from Sweden (Online 
Methods). We further informed this analysis with a much larger set of exome sequencing 
data from 45,376 individuals from multiple non-psychiatric cohorts ascertained by the 
Exome Aggregation Consortium8. This made it possible to identify among the Swedish 
research participants 244,246 coding-sequence and splice-site ultra-rare variants (URVs) that 
were present in single individuals – a set of variants that is greatly enriched for recent 
mutations, relative to the vastly larger fraction of heterozygosity that is due to less-rare 
variants (Fig. 1a). This large set of variants made it possible to identify broad biological 
patterns among an excess of more than 1,000 protein-damaging URVs that we found in the 
exomes of 4,946 individuals affected with schizophrenia.
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RESULTS
Exome-wide enrichment of ultra-rare variants
We analyzed the protein-coding sequences (the exomes) of 12,332 unrelated Swedish 
individuals, including 4,946 affected with schizophrenia (2,951 males and 1,995 females), 
6,242 unaffected controls (3,182 males and 3,060 females), and 1,144 affected with other 
disorders (443 males and 701 females, used for population genetic analyses but not as cases 
or controls). After removing 119 individuals for quality control reasons (mostly due to 
divergent ancestry, Online Methods), we identified 244,246 coding-sequence and splice-site 
URVs (among 4,877 schizophrenia cases and 6,203 controls) that were present in only one 
of the 12,332 unrelated Swedish exomes analyzed and never seen in the Exome Aggregation 
Consortium (ExAC) cohort (which numbered 45,376 individuals after excluding the subjects 
from this cohort and other subjects ascertained for psychiatric disorders).
We focused on URVs in most analyses because such variants – although comprising a tiny 
fraction (less than 0.2%) of the heterozygous sites in an individual – will be greatly enriched 
for recent mutations and thus have been exposed to fewer generations of purifying selection. 
The size of the Swedish cohort analyzed, and the additional sequence data for the Exome 
Aggregation Consortium, allowed us to greatly refine the identification of URVs; for 
example, among 5,092 (of the 12,332) individuals who were also part of an earlier 
sequencing study9, the additional data allowed us to re-classify ~66% of variants that had 
been “singletons” as segregating variants (not URVs in the current analysis). This may have 
been particularly helpful for refining analyses of challenging-to-interpret missense variants, 
as we describe below.
We classified coding-sequence and splice-site variants into four groups (Fig. 1b):
• synonymous: exonic variants not predicted to change the encoded protein 
(63,230 URVs);
• missense non-damaging: missense variants not predicted to damage 
protein function (by the criteria below) (134,100 URVs);
• damaging: missense variants predicted to compromise protein function per 
an algorithm (Online Methods), in-frame indels, or variants affecting 
protein-protein-contact domains (27,390 URVs); and
• disruptive: variants that truncate or abrogate the encoded protein in a way 
that is readily classified as loss-of-function10 or as triggering nonsense 
mediated decay (NMD)11. These included nonsense, frameshift, splice-
site, and very rarely, read-through variants. (19,526 URVs).
The terms protein-“damaging” and gene-“disruptive” refer to predicted effects on individual 
gene copies and the encoded proteins, rather than effects on phenotypes; effects on 
phenotypes can be inferred only from association analysis.
Missense damaging URVs accounted for approximately 15% of all missense URVs 
(Supplementary Fig. 1). There was a median of 2 disruptive and 2 damaging URVs per 
individual (4 total) (Supplementary Fig. 2).
Genovese et al. Page 3
Nat Neurosci. Author manuscript; available in PMC 2017 April 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
To assess whether schizophrenia was associated with an increased number of coding-
sequence and splice-site URVs (in specific genes, across the exome, or in sets of genes), we 
used a linear regression model to control for possible confounding variables, including each 
individual’s overall number of detected URVs (including non-coding URVs), sex, birth year, 
the hybrid selection kit used for exome enrichment, and the first 20 principal components 
estimated from exome-wide SNP and indel genotypes (Supplementary Table 1).
An important negative control – to address the possibility that analyses could be affected by 
population structure, differences in average relatedness within the case and control groups, 
or by technical variation – is to ask whether functionally neutral forms of variation show any 
apparent differences in frequency between case and control groups. We did not observe a 
significant difference in the rate of synonymous URVs between schizophrenia cases and 
controls (Fig. 1c). We also did not observe a significant difference for non-coding URVs 
(Supplementary Fig. 3a).
In contrast, we observed significant case-control differences in the rates of disruptive URVs 
(a difference of 0.12 variants/person; 95% confidence interval [CI]=0.07–0.17; P = 1.8 × 
10−6) and damaging URVs (0.12 variants/person; 95% CI=0.07–0.18; P = 3.4 × 10−5). (P 
values determined by permuting the phenotype data 10 million times agreed with P values 
from the linear regression analysis, and were: P = 0.81 for synonymous, P = 0.045 for 
missense non-damaging, P = 3.5 × 10−5 for damaging, and P = 1.8 × 10−6 for disruptive; this 
suggests that the P values from the regression model are well-calibrated) Damaging and 
disruptive URVs showed similarly elevated frequencies in cases and were thus combined 
into a single category termed dURVs (disruptive and damaging ultra-rare variants) for 
subsequent analyses.
Adjusting for covariates, there were 7% more dURVs in affected individuals than in controls 
(odds ratios [OR]=1.07; 95% CI=1.05-1.09; P = 1.5 × 10−10), as the case-associated 
elevation in dURVs (of about 0.25 variants/patient; 95% CI=0.17-0.32) occurred on a 
background of about 4 dURVs per patient. The elevated frequency of dURVs among 
individuals affected with schizophrenia appeared to arise from multiple types of dURVs, 
including in-frame indels, protein-protein-contact, splice-acceptor, splice-donor, stop-
gained, and frame-shift variants (Supplementary Fig. 3b).
To assure that this result was not the result of population stratification within Sweden, we 
further estimated the enrichment in a more genetically homogeneous subset of the Swedish 
cohort (3,554 schizophrenia cases and 5,164 controls) that excluded individuals with 
significant amounts of Finnish or Northern Sweden ancestry. Individuals with schizophrenia 
showed a similar dURV excess in this more genetically homogeneous group (excess of 0.25 
dURVs/case, 95% CI 0.16-0.34; P = 2.2 × 10−8).
We next estimated the extent to which dURVs tend to be inherited or de novo. While 
parental DNA would be necessary to directly ascertain which specific dURVs are de novo 
mutations (DNMs), we can compare the schizophrenia-associated elevation in dURVs 
(~0.25 per exome) to an analogous elevation in DNMs detected in earlier studies of 617 
affected and 1911 unaffected father-mother-offspring trios12,13. Using data from the trios, 
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we estimated the frequencies of DNMs that were protein-damaging or -disruptive (dDNMs) 
by the same criteria we used to identify dURVs (including restricting to variants not 
previously observed in ExAC8). These data yielded an elevation of about 0.03 such DNMs 
per exome, based on the difference between rates of 0.185 (95% CI 0.151-0.219) for 
individuals with schizophrenia12 and 0.156 (95% CI 0.139-0.174) for unaffected 
individuals13. This estimate (0.03 per exome) was several times smaller than the elevation of 
dURVs in affected individuals in our population-based study (0.25 per exome). (We note that 
such a comparison requires the imperfect assumption of uniform technical ascertainment 
across the sequencing studies; even under plausible relaxations of this assumption, the 
dURV excess greatly exceeds the dDNM excess. Also, when estimated by this same 
approach, rates of synonymous and non-damaging DNMs were similar – 0.475 in affected 
and 0.459 in unaffected individuals – suggesting that the analysis is well-calibrated.) We 
conclude that the great majority of the dURVs driving the elevated rates in schizophrenia 
were inherited rather than de novo, though the very-low allele frequency of these variants 
suggests that they are on average just a few generations old.
Although the elevated frequency of dURVs among affected individuals was statistically 
significant (P = 1.4 × 10−10), it was still only a modest increase of 0.25 dURVs on a 
background of about 4 dURVs per individual. This excess could in principle be concentrated 
in individual genes or in sets of functionally related genes, possibilities we address below.
Single gene burden analysis
Joint analysis of many rare variants that affect the same gene or sets of genes can increase 
power to identify genes whose disruption increases the risk of schizophrenia. To find 
individual genes that had significantly more rare variants in cases or controls, we performed 
a burden test using SKAT14 adjusting for previously defined covariates (Online Methods). 
We tested for (a) disruptive, (b) damaging, (c) disruptive and damaging, and (d) missense 
variants that were either (i) ultra-rare, (ii) singletons in the Sweden cohort, (iii) had a minor 
allele count ≤5 (minor allele frequency <0.02%), (iv) had a minor allele count ≤10 (minor 
allele frequency <0.05%), (v) had a minor allele frequency <0.1%, or (vi) had a minor allele 
frequency <0.5%.
Given the sample size, our analysis would have >90% power (at α = 2.5 × 10−6) to detect 
any gene for which rare, disruptive and damaging variants were present in 1% of 
schizophrenia cases, even if such variants had only a relatively modest effect size15 (odds 
ratio of at least 3, i.e. about 2% penetrance), and still greater power if effect sizes were 
larger. No individual gene surpassed exome-wide significance in this analysis 
(Supplementary Fig. 4), suggesting that no one gene is likely to have rare variants that 
explain even 1% of schizophrenia cases. The individual gene with the strongest enrichment 
was KL (klotho) (Supplementary Table 2), in which we found eight different dURVs in 
cases and none in controls (P = 3.7 × 10−4), but this result was not significant given the 
number of genes tested. Other models, based on higher levels of polygenicity, therefore 
appear to be more plausible: in a model in which a hypothetical gene is affected in 0.1% of 
schizophrenia cases, we would have only ~4% power to conclusively find this effect at 
exome-wide significance, and a far-larger sample would be required. The finding that no 
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individual gene surpassed exome-wide significance in this analysis (Supplementary Fig. 4), 
suggests that no one gene is likely to have rare variants that explain even 1% of 
schizophrenia cases.
Among genes previously reported to have potential connections between rare variants and 
schizophrenia, we identified an ultra-rare splice donor variant in TAF1312, an ultra-rare 
nonsense variant in SETD1A16,17, and a single ultra-rare nonsense variant in NRXN1, a 
gene in which exonic deletions associate with schizophrenia18. We did not find any evidence 
of enrichment of dURVs in DPYD19 (in which we found two dURVs in cases and six in 
controls), nor in DISC120 (one dURV among cases and two in controls) (Supplementary 
Table 3).
With this high level of polygenicity foreshadowed by earlier results9,16, it appears that 
definitive implication of individual genes will require sequencing still-larger numbers of 
exomes or whole genomes6. We therefore focused on sets of genes with plausibly 
overlapping biological functions as a way of concentrating a diffuse genetic signal.
Enrichment of variants from cases in constrained genes
We tested gene sets for an enrichment of dURVs (in cases relative to controls) by comparing 
each gene set’s enrichment level to that of the average gene (Online Methods). We made 
this stringent correction to account for the fact that any large gene set is more likely to 
encompass the exome-wide excess of dURVs we see in schizophrenia cases. Our practice 
greatly deflates the resulting P values.
Subsets of human genes have been previously identified as “missense constrained” (based on 
a lack of functional coding variation in controls) or “loss-of-function intolerant” (based on a 
smaller-than-expected number of loss-of-function mutations in population-scale data)13,21. 
Similar to recent findings in autism, we observed a significant enrichment (in cases relative 
to controls) of dURVs in missense constrained genes22 (OR=1.28; 95% CI=1.20–1.37; P = 
3.2 × 10−8) and loss-of-function intolerant genes8 (OR=1.17; 95% CI=1.12-1.21; P = 1.7 × 
10−8) (Fig. 2). Both missense constrained and loss-of-function intolerant genes were 
enriched for disruptive variants relative to damaging variants (Supplementary Fig. 5); for 
the latter set, this may reflect these genes having been ascertained specifically for 
intolerance to disruptive mutations.
In contrast, genes not meeting earlier criteria for loss-of-function intolerance or missense 
constraint were much less enriched for dURVs (Supplementary Fig. 6). This important 
negative control confirms that the schizophrenia-associated elevation we observe (for 
constrained genes) is not due to false positives disproportionally represented across 
disruptive and damaging variants in cases. The observed enrichment was consistent across 
data from previously analyzed exomes9 and newly generated data (Supplementary Fig. 5); 
as the previously analyzed exomes were sequenced across randomized batches with equal 
number of cases and controls in each batch, this provides additional evidence that the 
enrichment is not due to technical effects.
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Tissues and cell types
The excess of dURVs could in principle be concentrated in genes expressed within specific 
tissues. Distinct tissues have both shared and tissue-specific sets of expressed genes. We 
found that a set of 2,647 genes expressed specifically in brain tissue23 was strongly enriched 
for dURVs (OR=1.17; 95% CI=1.11–1.23; P = 1.2 × 10−4), whereas sets of genes with 
expression specific to other tissues (including immune cells) were not (Fig. 3a and 
Supplementary Fig. 7). (At the same time, the “brain-specific” genes explained only part of 
this signal, while a larger set of brain-expressed genes explained most of it, suggesting that 
much of the signal may come from genes that are expressed in brain as well as other tissues, 
Fig. 3a). This aligns with earlier findings that SNP haplotypes implicated in schizophrenia 
genome-wide association studies (GWAS) tend to overlap (to a non-random degree) with 
sequences identified as putative enhancers in chromatin-profiling experiments on brain 
tissue24,25.
The brain contains a complex mixture of cell types, each of which expresses different, only 
partially overlapping sets of genes. To identify cell types through which rare variants might 
act to affect risk of schizophrenia, we evaluated (for enrichment of dURVs in affected 
relative to unaffected individuals) sets of genes identified as specific to neurons, astrocytes, 
and oligodendrocytes by earlier cell sorting and transcriptional profiling experiments26. A 
set of 3,388 neuron-specific genes had a strong enrichment of mutations in schizophrenia 
cases (OR=1.17; 95% CI=1.12–1.22; P = 1.9 × 10−7), comparable to that observed for genes 
specific to brain tissue itself. Genes specifically expressed in other brain cell types, such as 
astrocytes and oligodendrocytes, were no more enriched than the average gene (Fig. 3b and 
Supplementary Fig. 8a). These results nominate neurons as the central nervous system 
(CNS) cell type in which genetic perturbations most affect schizophrenia risk, though they 
do not exclude more-modest contributions from other CNS cell types.
Neurons are broadly classified into excitatory and inhibitory classes. The case-control excess 
of dURVs showed a similar degree of concentration into genes expressed in excitatory and 
inhibitory neurons (Supplementary Fig. 8b). The small number of genes that were specific 
to excitatory or inhibitory neurons (relative to the other class) were insufficient to 
concentrate this genetic signal, which appeared to reside primarily in genes that were 
expressed in both neuronal classes (Supplementary Fig. 8b).
Synaptic mRNAs
A strong and consistent finding in exome-sequencing studies of schizophrenia involves an 
excess of variants in genes whose mRNAs are bound by the fragile X mental retardation 
protein (FMRP)9,12,27. The large excess of dURVs ascertained in the current set of 
schizophrenia cases elevated evidence for this relationship (OR=1.23; 95% CI=1.17–1.30; P 
= 8.2 × 10−9).
The enrichment of dURVs among genes that encode FMRP-bound transcripts has multiple 
potential biological explanations. One potential explanation could involve the translational-
inhibition capacity of FMRP, as implicit in the common description of such genes as FMRP 
“targets”. Another potential interpretation is that it is in fact the localization of these RNAs 
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to neuronal processes and synapses by FMRP – its shuttling activity – that defines the 
important biological commonality among these genes. Yet a third possibility is that FMRP-
binding experiments have simply been effective ways of ascertaining neuronally expressed 
genes.
To evaluate these possibilities, we first considered a different set of genes whose mRNAs are 
carried to synapses by a different shuttling protein, CELF428. The genes encoding CELF4-
bound mRNAs also showed an enrichment of dURVs in schizophrenia cases; this 
enrichment (OR=1.14; 95% CI=1.09–1.19; P = 6.6 × 10−4) was greater than that of the 
average gene though less strong than that of genes encoding FMRP-bound RNAs.
We also investigated whether genes encoding mRNAs that are bound by RBFOX splicing 
factors, known to regulate synaptic genes29 and also previously observed at synapses30, 
could explain a substantial fraction of the dURVs. Earlier experimental work (based on the 
HITS-CLIP technique for identifying RNAs bound to proteins of interest) has defined 
constellations of genes whose RNAs are bound by RBFOX1, RBFOX2, or RBFOX3. (We 
considered RBFOX1 and RBFOX3 together below due to their largely overlapping sets of 
bound genes31). Genes whose transcripts are bound by RBFOX1 or RBFOX3 were enriched 
in dURVs (OR=1.16; 95% CI=1.11–1.21; P = 6.7 × 10−7). A somewhat stronger enrichment 
was apparent for genes whose RNAs are bound by RBFOX2 (OR=1.21; 95% CI=1.16–1.26; 
P = 6.3 × 10−12).
We also observed enrichment in synaptic genes as defined by the SynaptomeDB32 
(OR=1.14; 95% CI=1.09–1.20; P = 0.0022), though this smaller set of genes explained a 
smaller fraction of the case-control difference in dURVs (Fig. 3c).
We were concerned that the enrichment for dURVs in genes with synaptically localized 
transcripts could, in principle, be simply due to these experiments having been highly 
effective at isolating transcripts that are present in neurons (which strongly express FMR1, 
CELF4, and RBFOX1/2/3); in this case, the importance of synaptic localization would be 
uncertain. To address this possibility, we identified, from earlier experimental data, sets of 
genes expressed in brain tissue23, neurons26, excitatory neurons, and inhibitory neurons33. 
Within each set, we defined a gene as “potentially synaptic” if it was in any of the previously 
constructed FMRP, CELF4, RBFOX2, or SynaptomeDB gene sets, then stratified each of the 
neuronal/brain expression gene sets based on whether or not the genes were potentially 
synaptic (Fig. 4). No matter how we defined neuronally expressed genes, we observed that 
this tendency to contain an excess of dURVs in schizophrenia cases distinguished the 
potentially synaptic genes (which showed elevated rates of dURVs in schizophrenia) from 
other neuronally expressed genes (which did not) (Fig. 4).
These large constellations of potentially synaptic genes appeared to explain a large fraction 
(collectively more than 70%) of the exome-wide enrichment in dURVs (Fig. 4).
Protein complexes
Protein complexes have been used to define sets of genes with aligned activities, offering 
potentially meaningful ways to group genes for genetic analysis. We focused on genes 
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encoding proteins that have been detected at synaptic complexes by co-immunoprecipitation 
with known synaptic components followed by mass spectrometric proteomic analyses. These 
gene sets have been the source of primary enrichment results in earlier studies of CNVs and 
rare and de novo SNVs in schizophrenia patients9,12,34. We observed case-control 
enrichment of dURVs among genes thus defined as encoding interactors with PSD-95 
(OR=1.52; 95% CI 1.21–1.90; P = 0.0017), ARC and N-methyl-D-aspartate receptors 
(NMDAR)35 (OR=1.55; 95% CI=1.21–1.98; P = 0.0028) (Fig. 2). Despite these elevated 
levels of enrichment, these smaller gene sets explained much smaller fractions (collectively 
4-12%) of the case-control enrichment in dURVs, perhaps reflecting that these gene sets 
include just a fraction of the proteins that are present at synapses.
More-complete ascertainment of the protein components of synaptic structures is an 
important future research direction that might advance functional analysis and interpretation 
of larger constellations of rare variants.
Overlap with GWAS genes and intellectual disability
We tested whether genes within the 108 GWAS loci recently identified in schizophrenia also 
contain an excess of dURVs. We observed a nominally significant enrichment in genes 
overlapping regions near common variants associated with schizophrenia24 (OR=1.37; 95% 
CI=1.09–1.73; P = 0.027) (Fig. 2) hinting at some degree of convergence. This overlap was 
greater than could be explained by any individual gene or small set of genes. Predicted 
targets of microRNA-13736, previously identified as localized near common SNPs 
associated with schizophrenia37, were also significantly enriched for dURVs (OR=1.13; 
95% CI=1.09–1.18; P = 6.8 × 10−4) (Fig. 2).
Mutations associated with intellectual disability and developmental disorders are often also 
substantial risk factors for syndromic forms of autism and perhaps schizophrenia38–40,17. We 
did observe the dURV elevation to be concentrated in X-linked intellectual disability (XLID) 
genes41,42 (OR=1.88; 95% CI=1.34–2.64; P = 9.5 × 10−4) and in developmental disorder 
(DD) genes43 (OR=1.67; 95% CI=1.31-2.13; P = 1.6 × 10−4) (Online Methods). Of 
potential interest, we identified four dURVs in schizophrenia cases (and none in controls) in 
XLID gene KDM5C, an H3K4 methylation eraser gene44, 11 dURVs in cases (and 2 in 
controls) in DD gene KDM5B, another H3K4 methylation eraser gene45, and 11 dURVs in 
cases (and 3 in controls) in DD gene ITPR1, which encodes an inositol triphosphate 
receptor46 (Supplementary Tables 2 and 3). The enrichment of XLID variants was not 
different between female and male cases (Supplementary Fig. 9).
Ovrelap with de novo mutations ascertained in trios
We further tested for enrichment of dURVs in (i) genes overlapping de novo copy number 
variants (CNVs) previously found in individuals with schizophrenia, bipolar disorder, and 
autism (Supplementary Tables 4 and 5, see Online Methods), and (ii) genes in which de 
novo non-synonymous mutations were previously ascertained in individuals with autism, 
congenital heart disease, epilepsy, intellectual disability, and schizophrenia (Supplementary 
Tables 6 and 7, see Online Methods). Because de novo non-synonymous mutations have 
been ascertained in such a large number of genes, we sought to increase specificity by 
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restricting this analysis to loss-of-function intolerant (LoF-intolerant) genes, as previously 
defined8. We observed a significant enrichment in genes within de novo deletions previously 
ascertained in schizophrenia cases (OR=1.34; 95% CI=1.13–1.59; P = 0.0052) (Fig. 5a), as 
well as an enrichment in loss-of-function intolerant genes with de novo non-synonymous 
mutations in schizophrenia cases (OR=1.41; 95% CI=1.25–1.60; P = 0.0011) (Fig. 5b).
DISCUSSION
By sequencing the exomes of 12,332 unrelated individuals from Sweden, including 4,946 
affected with schizophrenia, we observed an exome-wide burden of dURVs in schizophrenia 
cases. This excess rare-variant burden – approximately 0.25 such variants per person (on a 
background of 4 such variants) – was several times greater than the schizophrenia-associated 
elevation in rates of gene-disruptive and protein-damaging de novo mutations, suggesting 
that the observed excess arose mostly from inherited variants. For less-rare (segregating) 
variants of even modest allele frequencies, we were unable to detect any excess in affected 
relative to unaffected individuals, consistent with a previous analysis of non-ultra-rare 
exonic variants in other cohorts47.
The excess of dURVs in schizophrenia cases largely resided in brain-expressed genes, and 
more specifically in genes that are expressed in neurons, rather than in other CNS cell types 
(Fig. 6). It is possible that earlier associations to small, protein-interaction-defined gene sets 
(such as PSD-95, NMDAR and ARC9,12,34), which appear to explain combined a much-
smaller fraction of the exome-wide dURV burden in schizophrenia (collectively 4-12%), 
have been proxies for a far-wider set of rare-variant effects at synapses.
Most of the excess of dURVs in affected individuals’ exomes appeared to be concentrated in 
a larger set of genes encoding potentially synaptic proteins. Genes whose transcripts are 
bound by FMRP or CELF4 – which transport a subset of neuronal RNAs to neuronal 
processes and synapses – or RBFOX2 – which regulates many synaptic RNAs and has been 
observed at synapses – explained considerably larger fractions (collectively more than 70%) 
of the global rare-variant enrichment observed in cases. Genes encoding RNAs bound by 
FMRP or RBFOX proteins have previously been shown to be enriched for mutations in 
subjects with autism and/or schizophrenia48,9,12,13,49, though it has been unclear whether 
such potential effects are a small or a large fraction of strongly risk-increasing variants. 
While it is tempting to attribute the association of schizophrenia with dURVs in FMRP–
associated, CELF4–associated, and RBFOX2–associated genes to the specific biological 
activities of these proteins, we propose that their association may simply reflect the synaptic 
localization and function of the transcripts and proteins encoded by these genes.
We observed a significant overlap of the dURV excess with genes in which de novo non-
synonymous mutations and deletions have been found in schizophrenia cases. We also 
observed a significant enrichment across intellectual disability genes on the X chromosome 
and in developmental disorder genes. This enrichment is compatible with observations of the 
role of intellectual disability genes in some cases of autism38–40 and schizophrenia17, though 
the penetrance of such mutations for schizophrenia may be much less than their penetrance 
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for intellectual disability, and they may reside primarily in syndromic cases in which 
schizophrenia is preceded by other developmental disorders17.
The fact that an analysis of the current scale (4,877 cases, 6,203 controls, and 45,376 other 
genomes used to help identify ultra-rare variants) did not implicate individual genes of large 
effect in an unbiased exome-wide search – while documenting a very clear exome-wide 
elevation of hundreds of pathogenic variants across 4,877 individuals affected with 
schizophrenia relative to controls – lends further support to the emerging impression that the 
high polygenicity of schizophrenia extends to rare as well as common variants9,16. Because 
of the rareness of these variants and the infrequency with which any individual gene is 
affected by them – even among schizophrenia cases – the sequencing of much larger cohorts 
will be needed to identify the specific individual genes in which rare variants shape risk for 
schizophrenia.
ONLINE METHODS
Sample collection and sequencing
A total of 12,384 blood-derived DNA samples from Swedish research participants were 
collected from 2005 to 2013. Psychiatric cases with a diagnosis of schizophrenia or bipolar 
disorder were ascertained from the Swedish National Hospital Discharge Register as 
described in previous studies9,50, which captures all inpatient hospitalizations. Controls were 
randomly selected from population registers. Excluding subjects with bipolar disorder, age 
information at the time of DNA sampling was available for each individual. All subjects 
provided informed consent; institutional human subject committees approved the research 
(UNC IRB # 04-1465). All procedures were approved by the ethical committees in Sweden 
and in the United States.
The 12,384 samples collected were sequenced in twelve separate waves. The first wave 
employed an earlier version of the hybrid-capture procedure (Agilent SureSelect Human All 
Exon Kit), which targets ~28 million base pairs of the human genome, partitioned in 
~160,000 intervals, whereas the samples from the other waves used a newer version (Agilent 
SureSelect Human All Exon v.2 Kit), which targets ~32 million base pairs of the human 
genome, partitioned in ~190,000 intervals. The first wave was sequenced using Illumina 
GAII instruments and the remaining waves were sequenced using Illumina HiSeq 2000 and 
HiSeq 2500 instruments, with pair ended sequencing reads of 76 base pairs across all waves. 
Sequencing was performed at the Broad Institute of MIT and Harvard across the period of 
time from 2010 to 2013. With the exception of the first wave, we did not observe significant 
differences across waves and cases status beyond what could be explained by ancestry 
(Supplementary Fig. 10).
This cohort has been previously analyzed in relation to schizophrenia for common 
variants51,37,52,50,24 and copy number variants52,53, and in relation to somatic mosaic 
mutations54. Exome sequence data for approximately half of the individuals in the cohort 
had already been analyzed in relation to schizophrenia phenotype in a previous study9 and in 
a more recent study17.
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Preliminary quality control for individuals
Exome sequence data from 12,384 samples was aligned against the GRCh37 human genome 
reference with bwa aln 0.5.955 and further processed using the GATK framework56. 
Genotype calls were generated using GATK Haplotype Caller version 3.1-144-g00f68a3 and 
best practices57,58. Variants filtered out by the GATK Variant Quality Score Recalibration 
(VQSR) tool were excluded. Genotypes over sites with less than 10x sequencing coverage 
were set to missing. We identified and removed 4 duplicate individuals and 48 individuals 
with a first degree relationship (Supplementary Fig. 11) with other individuals in the cohort 
using the plink59,60 software. We then computed the number of ultra-rare single nucleotide 
polymorphysms (SNPs) and indels never observed in ExAC8 for each of the remaining 
12,332 samples and identified one individual with 1,757 ultra-rare SNPs and 22 ultra-rare 
indels from the sixth sequencing wave (see Supplementary Table S5F from Genovese et 
al.54), four individuals with between 92 and 127 ultra-rare indels from the first sequencing 
wave, five individuals from waves 11 and 12 with between 410 and 496 ultra-rare SNPs due 
to African ancestry. These 10 individuals were excluded from further analysis. The resulting 
individuals had a range of 5-259 ultra-rare SNPs and 0-19 ultra-rare indels (Supplementary 
Fig. 12a). We further removed 15 individuals for whom the reported sex and the inferred sex 
from inbreeding coefficients on the X chromosome mismatched (Supplementary Fig. 13), 
including 7 individuals with 47, XXY karyotype (Klinefelter syndrome), and 94 individuals 
with more than 100 URVs.
Association with common variants
A logistic regression model was used to estimate association between single variants and 
schizophrenia phenotype correcting for sex and the first five principal components using 
plink59,60. We identified two loci (Supplementary Fig. 14) with statistically significant 
associations (p<10−6) replicating a couple of common variants associations previously 
observed for this cohort50: a single variant rs281766 on chromosome 2 in the UTR5 of genes 
TYW5 and C2orf47, a variant in strong linkage disequilibrium with the seventh strongest 
independently associated variant in the largest meta-analysis for schizophrenia24, and seven 
variants in the MHC region around the HLA genes, also a region with extensive linkage to 
known causal variants associated with schizophrenia61.
Variant annotation
We annotated all genotyped variants with SnpEff 4.2 (build 2015-12-05)62 using Ensembl 
gene models from database GRCh37.75. We further annotated variants with SnpSift 4.2 
(build 2015-12-05)63 using annotations from database dbNSFP 2.964,65. Variants identified 
within transcripts from UCSC known genes66 were further classified into four groups:
• synonymous: whenever classified with synonymous effect by SnpEff
• missense non-damaging: whenever classified with missense effect but not 
classified as damaging (by the criteria below)
• putatively protein-damaging: whenever classified with MODERATE 
impact by SnpEff and further predicted as damaging by each among 
SIFT67, PolyPhen-268, LRT69, Mutation Taster70, Mutation Assessor71, 
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and PROVEAN72 algorithms or classified as either in-frame indels or 
protein-protein-contact variants73
• gene disruptive: whenever classified with HIGH impact by SnpEff with 
the exclusion of protein-protein-contact variants
Notice that FATHMM74 predictions included in dbNSFP were not used due to poor 
performance with respect to minor allele count (Supplementary Fig. 1) and a small number 
of variants defined as damaging by the predictor (Supplementary Fig. 3b). The final 
predictor performed better than all other individual predictors (Supplementary Fig. 3b) but 
it was not overfit as to be the best predictor for this cohort (Supplementary Fig. 15).
Estimation of principal components
Out of a total of 1,753,312 variants passing VQSR filters, 66,874 were identified as in 
common with variants from the 1000 Genomes project phase 1 dataset75 and included as 
part of the Omni2.5 genotype array. We used this subset of highly confident variants to 
estimate population stratification. We selected exclusively Omni2.5 polymorphic sites 
because more robust in the 1000 Genomes dataset to artifacts due to the heterogeneity of the 
sequencing technologies used within the 1000 Genomes project. We then further restricted 
to variants with minor allele frequency larger than 1% in both the Sweden and the 1000 
Genomes dataset and we pruned for variants in linkage disequilibrium using plink59,60 (with 
command line '--indep 50 5 2'). We then merged the Sweden and the 1000 Genomes dataset 
and computed principal components using plink and GCTA76 (Supplementary Fig. 12c-d). 
Estimated 3rd and 5th principal components corresponded to previously observed Finnish 
and Northern-Southern Sweden clines12 (Supplementary Fig. 12d), while 1st, 2nd, and 4th 
principal components corresponded to the three main principal components in the 1000 
Genomes project phase 1 distinguishing African, East Asian, and Native American ancestry. 
While principal components did correlate with overall amounts of URVs (Supplementary 
Fig. 12e-f), rather than removing individuals with exotic ancestry based on principal 
components loading, we simply removed individuals with more than 100 URVs and we 
included sex, year of birth (Supplementary Fig. 12b), exome capturing kit, the first 20 
principal component loadings, and the total number of URVs for each individual as 
covariates in all statistical analysis involving URVs and dURVs.
Quality control for common variants
Variants were excluded whether failing the GATK VQSR tool (117,629 variants), having 
inbreeding coefficient less than zero (that is, more observed heterozygotes than expected) 
while at the same time failing a Hardy-Weinberg disequilibrium test with a false discovery 
rate of 10−6 (8,306 additional variants), or whether associating with any of the 146 batches 
among which the cohort was split for sequencing in the sequencing facility at the Broad 
Institute (3,700 additional variants). Due to prevalent population stratification within 
batches, we estimated unusual associations with a logistic regression model including sex 
and the first 20 principal components loadings as covariates.
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Excess of dURVs
For each gene set, to estimate the excess of dURVs in cases with schizophrenia (or the odds 
ratios for schizophrenia phenotype) we used a linear (or logistic) regression model 
correcting for: (i) sex; (ii) overall URV count; (iii) birth year; (iv) the hybrid selection kit 
used to enrich for exome sequence; and (v) the first twenty principal components estimated 
from exome-wide SNP genotypes. When estimating P values, to estimate the importance of 
each gene set with respect to the observed exome-wide enrichment, we further corrected for 
exome-wide dURV count. This expedient allows to better estimate the importance of each 
gene set irrespectively of its size and to answer the more precise question of whether a gene 
set concentrates the exome-wide dURV enrichment better than the average gene.
Construction of gene sets
We used different resources to build the gene sets for which the burden of dURVs was 
computed:
1. For missense constrained genes we used genes from supplementary table 2 
of Samocha et al.22.
2. For loss-of-function intolerant (LoF-intolerant) genes we used genes from 
Lek et al.8 available online (ftp://ftp.broadinstitute.org/pub/ExAC_release/
release0.3/functional_gene_constraint/).
3. For genes with expression specific to the brain, we used expression table 
from supplementary data set 1 of Fagerberg et al.23 and we selected genes 
for which expression in brain was four times higher than the median 
expression across all 27 different tissues (Supplementary Fig. 7).
4. For brain genes with expression specific to neurons, we used expression 
table from supplementary table S3b of Cahoy et al.26 and we selected 
genes for which log-expression in Neurons P7n cell type was 0.5 greater 
than the median log-expression across 11 central nervous system cell types 
(Supplementary Fig. 8a).
5. For RBFOX2 and RBFOX1/3 gene sets we selected genes from 
supplementary table S1 of Weyn-Vanhentenryck et al.31 for which at least, 
respectively, one Rbfox2 tag count was measured greater than or equal to 
4, and one of the sum of Rbfox1 and Rbfox3 tag counts was greater than 
or equal to 12. A single gene set was generated for RBFOX1 and 
RBFOX3 due to high correlation between tag counts for the two genes.
6. Instead of using the classical FMRP Darnell gene set of 842 mouse genes 
from supplementary table S2A of Darnell et al.27 including all genes with 
FDR<0.01, we used a larger gene set of 1,285 mouse genes from 
supplementary table S2C of Darnell et al.27 including genes with 
FDR<0.1.
7. For CELF4 we used genes with “iCLIP occupancy” greater than 0.2 from 
supplementary table S4 of Wagnon et al.28.
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8. To create a gene set with synaptic genes we included 1,887 genes from the 
SynaptomeDB32 from the presynaptic proteins, presynaptic activezone, 
synaptic vesicles, and postsynaptic density categories.
9. To create a set of genes expressed in brain, we used expression table from 
supplementary data set 1 of Fagerberg et al.23 and we selected genes for 
which fragments per kilobase of transcript per million (FPKM) in brain 
was larger than 5.
10. To create a set of genes expressed in neurons, we used expression table 
from supplementary table S3b of Cahoy et al.26 and we selected genes for 
which log-expression in Neurons P7n cell type was larger than 9.
11. To create sets of genes expressed in excitatory and inhibitory neurons, we 
used expression table from Table S2 of Mo et al.33 and we selected genes 
for which the average transcripts per million (TPM) of, respectively, 
excitatory pyramidal neurons and inhibitory neurons, the latter including 
parvalbumin (PV)-expressing fast-spiking or vasoactive intestinal peptide 
(VIP)-expressing interneurons, was larger than 50. Similarly for sets of 
genes specific for each neuron type, we selected genes expressed more 
than 5 times the minimum expression observed across all types 
(Supplementary Fig. 8b).
12. To generate a list of predicted targets of microRNA-137, we used human 
targets with good mirSVR score from Betel at al.36 available online (http://
www.microrna.org/).
13. To generate PSD-95 complex gene sets, we used a gene list generated 
from human cortex biopsy data35 available online (http://
www.genes2cognition.org/db/GeneList/L00000049).
14. To compute a combined NMDAR and ARC complexes gene set, we used 
genes from Table S9 of Kirov et al.34.
15. For genes implicated in common variant association studies, we used 
genes overlapping 62 regions from the 108 regions known to be associated 
with schizophrenia24, for which the overlap yielded at most four genes.
16. To generate genes involved in X-linked intellectual disability (XLID) we 
used gene lists available online (see next section).
17. To generate genes involved in developmental disorder, we selected genes 
from supplementary table 3 of McRae et al.43.
18. For genes implicated in de novo CNV studies, we used genes overlapping 
de novo deletions and duplications identified in autism77–84 and identified 
in bipolar disorder and schizophrenia34,85–88 cases (Supplementary 
Tables 4 and 5).
19. For genes implicated in de novo nonsynonymous mutations from exome 
sequencing studies, we used genes identified as mutated in 
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autism13,49,89,90, epilepsy91,92, congenital heart disease93, intellectual 
disability94–97, and schizophrenia98,19,99,100,12 (Supplementary Tables 6 
and 7).
Enrichment in X-linked intellectual disability genes
We used three different resources available online to define X-linked intellectual disability 
(XLID) genes:
• XLID OMIM genes were defined as those genes causing mental 
retardation phenotype in the OMIM database101 (http://omim.org/
geneMap/X)
• XLID GCC genes were defined as those genes tested by the Greenwood 
Genetic Center102 (http://www.ggc.org/diagnostic/tests-costs/test-finder/
test-finder.html?id=242).
• XLID Chicago genes were those tested by the Genetic Services 
Laboratories of the university of Chicago103,41,42,104 (http://
dnatesting.uchicago.edu/tests/x-linked-non-specific-intellectual-disability-
sequencing-panel).
We tested for enrichment of dURVs in the above gene sets and in genes including all of the 
above gene sets, and seperately genes believed to escape and not escape X-inactivation in 
humans105, genes from OMIM including autosomal genes causing intellectual disability, and 
genes involved in developmental disorders through de novo mutations43. We tested for 
enrichment separately in males and females, as well as combined (Supplementary Fig. 9).
While XLID genes and developmental disorders genes were strongly enriched in 
schizophrenia cases, autosomally linked intellectually disability genes were not. This 
discrepancy might reflect a better characterization of intellectual disability genes on the X 
chromosome due to a more straightforward study design for how these genes where 
discovered. We also observed that XLID genes which escape X-inactivation were more 
enriched than other XLID genes. This might reflect a disproportionate contribution to 
intellectual disability and psychosis from dosage sensitive brain-related genes on the X 
chromosome106–108. We did not observe a difference in effect sizes between males and 
females.
Similarly to rare variants enrichment, common variants associated with schizophrenia are 
localized near XLID genes CNKSR2 and NLGN4X, both of which escape X inactivation, as 
well as non-XLID gene PJA124.
No detectable enrichment of less-rare variants
Given the strong case-control enrichment of dURVs in potentially synaptic genes, we used 
these genes to perform a sensitive evaluation of whether we could observe an increased 
burden of less-rare disruptive and damaging variants in the same set. Using a standard 
burden test for non-ultra-rare variants with minor allele count 10 or less and controlling for 
covariates, we observed no statistically significant enrichment of disruptive and damaging 
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variants in schizophrenia cases compared to controls (P = 0.59), wheareas the same test was 
highly significant when restricted to URVs (P = 1.7 × 10−19, without controlling for exome-
wide enrichment) (Supplementary Table 8).
Variance explained
While a predictor based on common variants24,109 explained 15% of the variance in 
schizophrenia liability in this cohort, a predictor based on the cumulative burden of dURVs 
in all genes explained only 0.48% (P = 1.5 × 10−10), and a similar predictor in potentially 
synaptic genes explained only 0.92% (Nagelkerke's coefficient of determination) (P = 6.3 × 
10−19). We also attempted to generate a polygenic score based on the cumulative number of 
dURVs in genes that had burden of dURVs in cases greater than or equal to controls. Using a 
leave-one-out strategy, the resulting predictor explained 0.47% (P = 2.3 × 10−10) of the 
phenotypic variability. These estimates are naturally lower bounds on the effect of rare 
variants; knowledge of the correct effect size of each variant would significantly increase the 
predictive value of dURVs, though obtaining such knowledge will require sequencing a 
vastly larger number of exomes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Ultra-rare variants distribution and association with schizophrenia
(a-b) Counts across coding-sequence and splice-site rare variants stratified by minor allele 
count across exome sequencing data from 12,332 individuals indicating (a) how many 
variants were observed in the ExAC cohort and (b) how many variants were classified as 
disruptive, damaging, missense non-damaging, and synonymous. (c) Observed enrichment 
in schizophrenia cases compared to controls for coding-sequence and splice-site URVs 
across the main four annotation types. Enrichment and P values were computed using a 
linear regression model (left panel) and a logistic regression model (right panel). Horizontal 
bars indicate 95% confidence intervals.
Genovese et al. Page 23
Nat Neurosci. Author manuscript; available in PMC 2017 April 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. dURVs enrichement in schizophrenia cases across selected gene sets
Excess per case and odds ratios for dURVs across loss-of-function intolerant (LoF-
intolerant) genes, missense constrained genes, protein complexes genes, genes associated 
through common variants, predicted microRNA-137 targets, and intellectual disability 
genes. Enrichment and P values were computed using a linear regression model (left panel) 
and a logistic regression model (right panel) using exome-wide dURV count as a covariate to 
correct for average exome-wide burden (dot-dashed line). Horizontal bars indicate 95% 
confidence intervals.
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Figure 3. dURVs enrichment in schizophrenia cases across tissue, brain cell type, and synaptic 
gene sets
Excess per case and odds ratios for dURVs across genes with higher expression in a given 
tissue (a), genes with higher expression in a given cell type (b), and genes expected to 
localize to synapses (c). Enrichment and P values were computed using a linear regression 
model (left panels) and a logistic regression model (right panels) using exome-wide dURV 
count as a covariate to correct for average exome-wide burden (dot-dashed line). Horizontal 
bars indicate 95% confidence intervals.
Genovese et al. Page 25
Nat Neurosci. Author manuscript; available in PMC 2017 April 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. dURVs enrichment in schizophrenia cases across brain cell type gene sets stratified by 
synaptic localization
Odds ratios for enrichment of dURVs across genes expressed in brain tissue, neuronal cells, 
inhibitory neurons, and excitatory neurons, stratified between genes recognized as synaptic 
and genes recognized as non-synaptic. Synaptic genes were defined as genes part of either 
the FMRP, RBFOX2, CELF4, or SynaptomeDB gene sets. Enrichment and P values were 
computed using a logistic regression model using exome-wide dURV count as a covariate to 
correct for average exome-wide burden (dot-dashed line). Horizontal bars indicate 95% 
confidence intervals. Across each gene set, synaptic genes are clearly more enriched for 
variants in schizophrenia cases than non-synaptic genes.
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Figure 5. dURVs enrichment in schizophrenia cases across genes previously observed as affected 
by de novo mutations
Odds ratios for enrichment of dURVs across (a) genes overlapping de novo deletions and 
duplications in schizophrenia, bipolar disorder, and autism trios, and across (b) loss-of-
function intolerant (LoF-intolerant) genes with observed de novo mutations in 
schizophrenia, intellectual disability, congenital heart disease, epilepsy, and autism trios. 
Enrichment and P values were computed using a logistic regression model using exome-
wide dURV count (a) and dURV count across LoF-intolerant genes (b) as a covariate to 
correct for average burden (dot-dashed line). Horizontal bars indicate 95% confidence 
intervals.
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Figure 6. Dissection of the dURVs enrichment in schizophrenia cases
An enrichment of URVs in the exomes of individuals affected with schizophrenia (relative to 
variants in control exomes) is observed exclusively in dURVs. After correcting for exome-
wide dURV count, this enrichment is observed as concentrated in brain-specific genes while 
not in other tissue-specific genes, in neuron-specific genes while not in other brain-cell type-
specific genes, and finally in potentially synaptic genes while not in other neuronally 
expressed genes.
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